ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsReliable data on viral hepatitis-related deaths remain limited, challenging assessment of progress towards the WHO elimination targets for mortality. To address this gap, we estimated hepatitis B- and C-attributable mortality in Italy, Romania, and Spain for 2022.
methodsRetrospective hospital data on decompensated cirrhosis and hepatocellular carcinoma cases were collected from sentinel sites in each of three countries using standard WHO protocol. The data were used to calculate fractions of these diseases attributable to hepatitis B and C. Adjusted and weighted attributable fractions were applied to national vital statistics data on deaths from cirrhosis and hepatocellular carcinoma from Eurostat to produce national hepatitis mortality estimates.
resultsA total of 1733 cases of decompensated cirrhosis and hepatocellular carcinoma cases were enrolled into the study from sentinel sites across Italy, Romania, and Spain. We estimated that the share of decompensated cirrhosis deaths attributed to hepatitis B was: 8.7% in Italy, 16.8% in Romania and 1.8% in Spain. The respective share of hepatocellular carcinoma deaths attributed to hepatitis B was 19.0% in Italy, 31.2% in Romania and 4.9% in Spain. Hepatitis C accounted for 61.6% of hepatocellular carcinoma deaths in Italy, 36.5% in Romania, and 31.1% in Spain, as well as 32.9% of decompensated cirrhosis deaths in Italy, 18.8% in Romania and 12.7% in Spain. Overall, hepatitis B-related mortality per 100 000 population was 3.1 in Italy, 12.0 in Romania and 0.6 in Spain. Hepatitis C-related mortality was 11.4 per 100 000 population in Italy, 13.8 in Romania and 3.7 in Spain.
conclusionsOur study yielded empirical data needed to estimate hepatitis mortality for assessing the impact of hepatitis strategies. Whilst our results indicate a reduction in deaths related to hepatitis B and C in Italy and Spain, none of the three countries was meeting the WHO's 2025 target for hepatitis C-related mortality, although the hepatitis B-related mortality target was met by Italy and Spain. Our findings highlight the need for countries to continue strengthening efforts to prevent and control viral hepatitis and to integrate such assessments into national surveillance to guide effective targeting of interventions and monitoring of progress towards the elimination targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.